A functional polymorphism of the brain derived neurotrophic factor gene and cortical anatomy in autism spectrum disorder by Raznahan, Armin et al.
A functional polymorphism of the brain derived
neurotrophic factor gene and cortical anatomy
in autism spectrum disorder
Armin Raznahan & Roberto Toro & Petra Proitsi &
John Powell & Tomas Paus & Patrick F. Bolton &
Declan G. M. Murphy
Received: 28 January 2009 /Accepted: 29 March 2009 /Published online: 14 May 2009
# Springer Science + Business Media, LLC 2009
Abstract Autism Spectrum Disorder (ASD) is associated
with both (i) post-mortem and neuroimaging evidence of
abnormal cortical development, and (ii) altered signalling in
Brain Derived Neurotrophic Factor (BDNF) pathways -
which regulate neuroproliferative and neuroplastic process-
es. In healthy controls genotype at a single nucleotide
polymorphism that alters BDNF signalling (Val66met) has
been related to regional cortical volume. It is not known
however if this influence on brain development is intact in
ASD. Therefore we compared the relationship between
genotype and cortical anatomy (as measured using in vivo
Magnetic Resonance Imaging) in 41 people with ASD and
30 healthy controls. We measured cortical volume, and its
two sole determinants - cortical thickness and surface area -
which reflect differing neurodevelopmental processes. We
found “Group-by-Genotype” interactions for cortical vol-
ume in medial (caudal anterior cingulate, posterior cingu-
late) and lateral (rostral middle, lateral orbitofrontal, pars
orbitalis and pars triangularis) frontal cortices. Furthermore,
within (only) these regions “Group-by-Genotype” interac-
tions were also found for surface area. No effects were
found for cortical thickness in any region. Our preliminary
findings suggest that people with ASD have differences
from controls in the relationship between BDNF val66met
genotype and regional (especially frontal) cortical volume
and surface area, but not cortical thickness. Therefore
alterations in the relationship between BDNF val66met
genotype and surface area in ASD may drive the findings
for volume. If correct, this suggests ASD is associated with
a distorted relationship between BDNF val66met genotype
and the determinants of regional cortical surface area –
gyrification and/or sulcal positioning.
Keywords Autism.Brain.Brainderivedneurotrophic
factor.MRI
Introduction
ASD is a group of increasingly recognised [1] lifespan
persistent [2] neurodevelopmental disorders of early onset
[3, 4] characterised by abnormalities in language, social
interaction and a range of stereotyped and repetitive
behaviours [5]. The biological basis of ASD remains poorly
understood. However, autism (the paradigmatic ASD) is
both highly heritable [6], and associated with alterations in
both pre-natal brain development [7] and post-natal brain
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London, UKstructure [8, 9]. Despite this, little is known regarding the
influence of specific genes on brain anatomy in ASD with
the exception of the serotonin transporter [10]a n d
monoamine oxidase [11] genes which contain functional
genetic variants that have been associated with cortical
volume in children with ASD.
A strong and as yet unexamined candidate gene for
modulating brain anatomy in ASD is Brain Derived
Neurotrophic Factor (BDNF) which plays a key role in
neurogenesis, cortical lamination, synaptic plasticity, and
neuron survival [12]. Intracellular packaging and secretion
of BDNF is altered by a common functional [13, 14] non-
synonymous single nucleotide polymorphism (SNP) within
the 5′ region of the gene (BDNF val66met) which codes for
a valine to methionine substitution. In the healthy popula-
tion, genotype at this polymorphism has been associated
with differences in cortical plasticity [15] and regional
cortical volume (CV) [16–21] (see Table 1). Many of the
cortical areas where BDNF val66met genotype influences
CV in typically developing individuals overlap with those
where structural differences have been reported between
people with ASD and typically developing controls.
For example three independent studies [16, 17, 19] have
reported regional cortical CV reductions in BDNF met
carriers compared to val homozygotes in regions such as
the dorso-lateral and inferior frontal, superior parietal and
precuneus cortices. These are cortical regions where our
group [22], and others [23] that have shown structural
differences between people with ASD and healthy controls.
Furthermore, all [24–28] but one [29] of the studies
examining BDNF measures in ASD report abnormalities.
Autism Spectrum Disorder has been associated with (i)
elevated serum BDNF in infancy [24] childhood and
adulthood [25, 26], (ii) elevated blood lymphocyte BDNF
mRNA in young adults [30], and (iii) increased basal
forebrain BDNF levels in post-mortem samples of cerebral
cortex [28].
Therefore, it is possible that altered BDNF signalling in
ASD contributes to the anatomical differences of people
with ASD by disturbing the pathways through which the
BDNF val66met polymorphism influences regional CV. It
is not known however if the CV correlates of BDNF
val66met genotype differ between people with ASD and
typically developing controls. Therefore, we carried out a
preliminary exploratory investigation in which we related
BDNF val66met genotype to 33 regional measures of CVin
71 individuals – 41 of whom had an ASD diagnosis (35
with Asperger syndrome, four with high-functioning autism
and two with other pervasive developmental disorders), and
30 typically developing controls. Furthermore, in those
regions where there were significant differences between
people with ASD and controls in the relationship between
BDNF val66met genotype and CV – we also examined if
these were accompanied by alterations in cortical thickness
(CT) or surface area (SA). The volume of a cortical region
is approximated by the product of the total surface area and
the mean cortical thickness of that region.
Because these two sole determinants of CV reflect
distinct evolutionary and developmental processes [31, 32]
– it is important to disambiguate their relative contribution
to any differences in the CV correlates of BDNF val66met
genotype in people with ASD and controls. For example,
SA is influenced by division of progenitor cells in the
embryological periventricular area and varies as a function
First
Author
Year Sample Size Age
(years)
Gender Measure Findings
ValVal Met
Pezawas 2004 69 42 M: 34
R: 18-60
mixed VBM Met carriers - Reduced CV in bilateral
inferior and middle frontal gyri,
left precuneus and superior parietal
lobule, right medial frontal, precentral,
superior frontal, postcentral gyri. Val
homozygotes - Reduced CV in right
middle frontal and lingual gyri.
Agartz 2006 66 30 M: 42 mixed Automated
lobar CV
No significant effect of genotype
Nemoto 2006 41 68 M: 36
R: 20-72
mixed VBM Met carriers - reduced CV in left
parahippocampal gyrus.
Varnas 2008 73 31 M: 42 mixed Cortical
Thickness
Trend towards association between
genotype and CV in left frontal
(straight gyrus, transverse frontopolar,
superior frontal) and right frontal
(pars triangularis) cortices. No effect
of genotype on regional CT
Schofield 2008 96 59 M: 32
R: 20-60
mixed VBM No effect of genotype in regional CV
Table 1 Studies in healthy con-
trols relating BDNF val66met
to cortical
Abbreviations: M Mean,
R Range, VBM Voxel Based
Morphometry, CV Cortical
Volume, CT cortical thickness
216 J Neurodevelop Disord (2009) 1:215–223of brain volume and cortical folding (gyrification). In
contrast, CT is likely to reflect dendritic arborization/
pruning within the grey matter [33] or myelination at the
grey/white matter interface [34].
Materials and methods
Subjects
We included 41 subjects with ASD and 30 healthy controls.
All people with ASD were recruited through a hospital-
based national clinic and a university department special-
ising in the assessment of ASD with infrastructure support
from the Medical Research Council United Kingdom
Autism Imaging Multicentre Study (MRC UK A.I.M.S)
program. All cases were diagnosed clinically with Asperger
syndrome (n=35), autism (n=4), or Pervasive-
Developmental Disorder-not otherwise specified (n=2)
according to DSM-IV criteria. Diagnoses were made by a
team of senior clinicians trained in the Autism Diagnostic
Interview-Revised (ADI-R) (Le Couteur et al. 1989) and
the Autism Diagnostic Observation Schedule (ADOS-G)
(Lord et al. 2000). Twenty-four of the participants with
ASD also agreed to confirmation of clinical diagnosis
using the ADI-R or ADOS. Typically developing healthy
controls were recruited through advertisement in the
community.
Participants in the study underwent structured physical
and psychiatric examination (for the presence of a co-morbid
DSM-IV Axis I or II disorder). Participants did not have a
history of physical or psychiatric disorder affecting brain
function (e.g., epilepsy or psychosis), or a genetic disorder
putatively associated with autistic spectrum disorders (e.g.,
Fragile X syndrome). All participants had full-scale intelli-
gence quotients above 70. All subjects (or guardians where
applicable) gave informed and written consent.
There were no statistically significant differences in
mean age between cases and controls or between BDNF val
homozygotes and BDNF met carriers. Demographic and
cognitive details for all participants are given in Table 2.
Genotyping
The BDNF val66met genotype was determined using a
TaqMan allele specific assay method (Applied Biosystems)
according to the manufacturer’s protocols. Polymerase
chain reaction (PCR) amplifications were performed on an
ABI PRISM
® 7000 Sequence Detection System (Applied
Biosystems) with the reaction mixture in a total volume of
2μl, consisting of 5 ng of genomic DNA, 2×Universal
PCR Master Mix (ABGENE), 40× TaqMan SNP Genotyp-
ing Assay Mix (Applied Biosystems), and deionized H2O.
After denaturing at 95°C for 15 min, 50 cycles of PCR
were performed under the following conditions: 92°C for
15 s and 60°C for 90 s. All genotypes were reported with
the allelic discrimination program using the Applied
Biosystems Sequence Detection System (SDS).
Magnetic resonance imaging
Brain MRIs were acquired using a GE Signa 1.5 T neuro-
optimised MR system (General Electric, Milwaukee WI,
USA). “Freesurfer” freeware (http://surfer.nmr.mgh.
harvard.edu/fswiki) was used to derive models of the
cortical sheet in each T1-weighted image and parcellate
out the cortex into 33 regions. These well-validated [35, 36]
and fully automated procedures have been extensively
described elsewhere [37, 38], and we will only provide a
brief description here. Firstly, a surface reconstruction was
made for each scan [39]. This involved intensity normal-
isation, the removal of extra-cerebral tissues using a “skull
stripping” algorithm, and image segmentation using a
connected components algorithm. The output of this stage
is a single filled white-matter volume for each cerebral
hemisphere. A surface tessellation was then generated for
each white- matter volume by fitting a deformable template.
The grey matter/CSF surface was also modelled using a
similar process. Given explicit models for the white/grey
and grey/CSF surfaces, the measure of absolute cortical
thickness at any given point on the white/grey matter
surface is then taken to be the shortest distance between
that point and the grey/CSF surface. This measurement is
made at approximately 150,000 points across each hemi-
sphere for each scan.
In order to achieve automated parcellation of each
individual cortical hemispheric sheet into 33 regions [38],
Table 2 Subject characteristics
Characteristic CASES CONTROLS
Number 41 30
Male 34 26
Age at scan in years
Mean 34.64 27.5
Range 12–64 12–51
Standard deviation 12.55 11.89
FSIQ
Mean 104.58 126.5
Range 73–135 83–155
Standard deviation 17.23 19.09
Genotype
BDNF Val Val 31 19
BDNF Met carrier 10 11
J Neurodevelop Disord (2009) 1:215–223 217T
a
b
l
e
3
R
e
s
u
l
t
s
f
o
r
a
n
a
l
y
s
e
s
o
f
c
o
v
a
r
i
a
n
c
e
f
o
r
r
e
g
i
o
n
a
l
c
o
r
t
i
c
a
l
m
e
a
s
u
r
e
s
R
E
G
I
O
N
M
E
A
S
U
R
E
V
O
L
U
M
E
S
U
R
F
A
C
E
A
R
E
A
T
H
I
C
K
N
E
S
S
G
R
O
U
P
B
D
N
F
G
x
B
G
R
O
U
P
B
D
N
F
G
x
B
G
R
O
U
P
B
D
N
F
G
x
B
F
p
F
p
F
p
F
p
F
p
F
p
F
p
F
p
F
p
B
a
n
k
S
T
S
4
.
8
2
0
.
0
3
1
.
9
9
0
.
1
6
1
.
5
9
0
.
2
1
C
a
u
d
A
n
t
C
i
n
g
0
.
0
2
0
.
8
9
0
.
6
1
0
.
4
4
6
.
3
1
0
.
0
1
0
.
1
1
0
.
7
4
0
.
4
6
0
.
5
0
8
.
4
4
0
.
0
0
5
0
.
0
0
0
.
9
5
0
.
0
0
0
.
9
9
0
.
1
5
0
.
7
0
C
a
u
d
M
i
d
F
r
4
.
1
5
0
.
0
5
1
.
0
3
0
.
3
1
0
.
7
3
0
.
4
0
C
u
n
e
u
s
0
.
2
7
0
.
6
0
0
.
0
2
0
.
9
0
0
.
1
4
0
.
7
1
E
n
t
o
r
h
i
n
a
l
0
.
3
0
0
.
5
9
0
.
2
7
0
.
6
0
0
.
0
1
0
.
9
1
F
u
s
i
f
o
r
m
2
.
9
7
0
.
0
9
0
.
1
8
0
.
6
7
0
.
9
2
0
.
3
4
I
n
f
P
a
r
4
.
1
2
0
.
0
5
2
.
3
9
0
.
1
3
0
.
0
6
0
.
8
1
I
n
f
T
e
m
p
0
.
2
8
0
.
6
0
2
.
3
5
0
.
1
3
1
.
9
9
0
.
1
6
I
s
t
h
C
i
n
g
2
.
5
3
0
.
1
2
4
.
4
7
0
.
0
4
3
.
3
4
0
.
0
7
L
a
t
O
c
c
i
p
5
.
0
4
0
.
0
3
1
.
0
1
0
.
3
2
0
.
4
3
0
.
5
1
L
a
t
O
r
b
F
r
0
.
5
0
0
.
4
8
0
.
2
3
0
.
6
3
5
.
2
5
0
.
0
3
0
.
4
9
0
.
4
9
0
.
2
3
0
.
6
3
5
.
2
5
0
.
0
3
0
.
5
1
0
.
4
8
0
.
2
7
0
.
6
1
0
.
1
6
0
.
6
9
L
i
n
g
u
a
l
1
.
1
9
0
.
2
8
0
.
2
4
0
.
6
3
0
.
1
4
0
.
7
1
M
e
d
O
r
b
F
r
0
.
0
3
0
.
8
6
0
.
6
3
0
.
4
3
1
.
7
3
0
.
1
9
M
i
d
T
e
m
p
1
.
8
4
0
.
1
8
0
.
2
2
0
.
6
4
0
.
8
4
0
.
3
6
P
a
r
a
h
i
p
p
0
.
5
0
0
.
4
8
0
.
9
2
0
.
3
4
4
.
2
3
0
.
0
4
0
.
0
6
0
.
9
4
0
.
6
8
0
.
4
1
2
.
4
7
0
.
1
2
0
.
7
2
0
.
4
0
0
.
6
4
0
.
4
3
0
.
7
8
0
.
3
8
P
a
r
a
c
e
n
t
r
a
l
3
.
7
7
0
.
0
6
2
.
7
6
0
.
1
0
1
.
2
7
0
.
2
7
P
a
r
s
O
p
e
r
c
0
.
8
0
0
.
3
7
0
.
7
2
0
.
4
0
1
.
0
5
0
.
3
1
P
a
r
s
O
r
b
i
t
0
.
6
6
0
.
4
2
2
.
5
8
0
.
1
1
4
.
7
7
0
.
0
3
0
.
1
4
0
.
7
1
1
.
3
2
0
.
2
5
4
.
3
6
0
.
0
4
1
.
2
9
0
.
2
6
1
.
1
9
0
.
2
8
0
.
7
8
0
.
3
8
P
a
r
s
T
r
i
a
n
g
0
.
0
8
0
.
9
3
0
.
0
7
0
.
8
0
4
.
1
7
0
.
0
5
0
.
0
0
0
.
9
9
0
.
0
1
0
.
9
2
5
.
4
6
0
.
0
2
0
.
1
2
0
.
7
6
0
.
0
1
0
.
9
4
0
.
0
5
0
.
8
3
P
e
r
i
C
a
l
c
1
.
4
1
0
.
2
4
0
.
1
5
0
.
7
0
0
.
4
6
0
.
5
0
P
o
s
t
C
e
n
t
r
a
l
0
.
9
7
0
.
3
3
0
.
0
0
0
.
9
9
0
.
0
2
0
.
9
0
P
o
s
t
C
i
n
g
0
.
5
2
0
.
4
8
0
.
5
6
0
.
4
6
4
.
1
6
0
.
0
5
0
.
2
8
0
.
6
0
0
.
2
8
0
.
6
0
7
.
4
0
0
.
0
0
8
0
.
9
0
0
.
3
7
0
.
5
9
0
.
4
4
0
.
3
5
0
.
5
6
P
r
e
C
e
n
t
r
a
l
3
.
0
6
0
.
0
9
0
.
4
2
0
.
5
2
0
.
0
0
.
3
5
P
r
e
c
u
n
e
u
s
3
.
4
8
0
.
0
7
1
.
4
5
0
.
2
3
2
.
3
3
0
.
1
3
R
o
s
t
r
A
n
t
C
i
n
g
0
.
2
0
0
.
6
6
1
.
4
0
0
.
2
4
0
.
2
7
0
.
6
1
R
o
s
t
r
M
i
d
F
r
0
.
1
8
0
.
6
7
0
.
0
3
0
.
8
7
4
.
3
0
0
.
0
4
0
.
0
1
0
.
9
1
0
.
0
5
0
.
8
2
5
.
3
0
0
.
0
2
0
.
8
7
0
.
3
6
0
.
0
0
0
.
9
9
0
.
3
4
0
.
5
6
S
u
p
F
r
1
.
2
3
0
.
2
7
1
.
8
2
0
.
1
8
0
.
8
9
0
.
3
5
S
u
p
P
a
r
0
.
2
0
0
.
6
6
0
.
0
8
0
.
7
9
1
.
6
5
0
.
2
0
S
u
p
T
e
m
p
0
.
1
7
0
.
6
8
0
.
5
8
0
.
4
5
0
.
7
0
0
.
4
1
S
u
p
r
a
M
a
r
g
0
.
2
6
0
.
6
2
3
.
3
3
0
.
0
7
0
.
3
9
0
.
5
4
F
r
o
n
t
a
l
P
o
l
e
0
.
0
3
0
.
8
7
0
.
1
4
0
.
7
1
0
.
0
7
0
.
8
0
T
e
m
p
P
o
l
e
0
.
0
7
0
.
7
9
0
.
8
2
0
.
3
9
0
.
5
1
0
.
4
8
T
r
a
n
s
v
T
e
m
p
0
.
6
6
0
.
4
2
1
.
8
4
0
.
1
8
1
.
1
1
0
.
3
0
218 J Neurodevelop Disord (2009) 1:215–223a probabilistic atlas was placed within a surface-based co-
ordinate system to which each scan was aligned. Parcella-
tion generated a measure of total CV, total SA and average
CT for each sub-region within each hemisphere. For each
sub-region values for left and right hemispheres were
combined, resulting in a total of three measures (SA, CT
and GV) for each of 33 sub-regions.
Statistical analyses
Analyses of covariance (ANCOVAs) were used to model
the effects of Group (ASD vs controls), BDNF genotype
(Val vs Met carriers) and the interaction of these two terms
on regional measures of CV. In order to limit the number of
statistical tests, we combined measures of CV for each of
33 cortical regions per hemisphere into total bilateral CV
for that region. Given the exploratory nature of this analysis
we adopted an uncorrected p value of 0.05. For those
regions showing significant “Group by Genotype” interac-
tion effects, we carried out further ANCOVA’s for CT and
SA in order to establish which of these parameters may be
contributing to “Group-by-Genotype” effects for CV
(again, applying an uncorrected p value of 0.05). Cortical
volume, SA and CT were not transformed before being
used as dependent variables in these analyses.
Within this cross-sectional dataset, we were not able to
identify the non-linear age effects reported in much larger,
longitudinal studies[40]. Linear age effect were however
seen and given the wide age-range of our sample, age was
included as a co-variate to remove variance not related to
our independent variables of interest. As there were no
significant differences between groups in gender, or
intracranial volume (ICV) – we did not co-vary for these
in analyses. Furthermore, the relationships between ICV
and CV, SA/gyrification and CT are complex, non-linear
[41] and may differ with age and gender [42].
Results
Neither group, genotype, not the interaction of these two
terms was associated with total intracranial volume, total
cortical volume, total cortical surface area or mean cortical
thickness.
There was a significant “Group by Genotype” interaction
for CV in six cortical areas - posterior cingulate, caudal
anterior cingulate, rostral middle frontal, lateral orbitofron-
tal, pars orbitalis and pars triangularis. Further, within all of
these regions, significant “Group by Genotype” interactions
were also found for SA, but not CT (Table 3). In order to
determine how specific “Group-by-Genotype” interactions
for SA were to those regions also showing interactions for
CV, we next ran ANCOVAs for SA in all cortical regions.
No other areas showed a “Group-by-Genotype” interaction
for SA (results not shown but available).
In all six regions “Group by Genotype” interactions for
both CV and SA reflected the same phenomenon – lower
CV/SA in control BDNF met allele carriers compared to
control BDNF val homozygotes, but higher CV/SA in ASD
BDNF met allele carriers as compared to ASD BDNF val
homozygotes. The same pattern was seen in all six regions
and is illustrated in Fig. 1 using the caudal anterior
cingulated as an example.
Discussion
The results from our exploratory study suggest that the
relationship between cortical anatomy and BDNF genotype
may differ between people with ASD and typically
developing controls. Given the preliminary nature of our
investigation we did not correct for multiple comparisons,
and so replication is required. Nevertheless, our findings do
lead to testable hypotheses.
Firstly, rather than being generalised, “Group-by-Geno-
type” interactions may be most marked in particular
cortical regions, i.e the caudal anterior cingulate, posterior
cingulate, rostral middle frontal, lateral orbitofrontal, pars
orbitalis and pars triangularis. These regions are not
scattered across the cortex, but describe two larger
contiguous frontal areas – one medial and one lateral.
Secondly, many of the cortical regions where we
identified “Group-by-Genotype” interactions for CV/SA
overlap with those where BDNF has been shown to
modulate CV in typically developing by structural MRI
[eg in the medial, middle and inferior frontal [16, 17, 19]],
and N-acetylaspartate levels (a marker of neuronal
integrity) in healthy controls by Magnetic Resonance
Spectroscopy [anterior cingulate [43]]. In our sample the
relationship between CVand BDNF val66met genotype in
controls was in the same direction and similar frontal
distribution as that reported in other samples of typically
developing individuals [16, 17]. That is in controls CV
was reduced in BDNF met allele carriers compared to
BDNF val allele homozygotes. This relationship was
reversed in people with ASD. Furthermore, cortical
regions where we identified “Group-by-Genotype” inter-
actions for CV/SA also overlap with those where com-
pared to controls, people with ASD have been reported as
showing alterations in CV [23], cortical folding [44]a n d
magnetic resonance spectroscopy measures of neuronal
integrity [anterior cingulate [45]]. This suggests that
differences in cortical structure between people with
ASD and typically developing controls may be due to
differences in BDNF val66met genotype frequency and/or
function.
J Neurodevelop Disord (2009) 1:215–223 219Thirdly, in those (and only those) regions showing
significant “Group x Genotype” interactions for CV, we
also found significant “Group x Genotype” interactions for
SA, but not CT. This suggests that the CV findings are
driven by “Group x Genotype” interactions for SA. The SA
within a given cortical region may be altered in three ways;
(i) alterations in radial brain size, (ii) displacement of the
landmarks (eg sulcal landmarks) used to define regional
boundaries, or (ii) increased gyrification of the cortical
sheet within unaltered regional boundaries.
We did not identify any “Group-by-Genotype” interac-
tions for intracranial volume or total cerebral SA (data not
shown but available), which argues against the first of these
explanations. The remaining two explanations are compat-
ible with existing reports of altered sulcal positioning [46]
and gyrification [47] in people with ASD compared to
Fig. 1 Caudal anterior and posterior cingulate CVand SA by Group and BDNF genotype. Bars represent 95% confidence intervals for mean CV/
SA
220 J Neurodevelop Disord (2009) 1:215–223controls. As both of these cortical characteristics can be
quantified from MRI scans – their relative contributions to
putative differences in the SA correlates of BDNF val66met
genotype between people with ASD and controls can be
directly examined in future work.
The mechanisms that could underlie differences between
people with ASD and controls in the CV/SA correlates of
BDNF val66met genotype are unclear. Such differences
could be due to abnormal BDNF signalling in ASD causing
disruption of the pathways through which the BDNF
val66met polymorphism might influence cortical structure
during typical development such as neuronal migration [48]
and/or experience dependent plasticity [49]. Alternatively,
our findings may not be due to abnormal BDNF signalling
in ASD per se, but reflect the fact that brain structure is so
atypical in ASD that the subtle differences accounted for by
any given single genetic polymorphisms are “drowned out”
(Raznahan et al, in press). A further possibility is that due
to dysfunction within molecular pathways that interact with
BDNF to influence brain development – the typical
downstream effects of differences in BDNF signalling due
to val66met genotype are not seen in ASD. Autism
Spectrum Disorder has been associated with reports of
abnormalities within several discrete molecular systems that
all share the feature of directly impacting on or interacting
with BDNF transcription and function. These include
serotonin (5HT) [50, 51], Calcium-dependent activator
protein for secretion 2 (CAPS2) [52, 53], methyl-CpG
binding protein 2 (MeCP2) [14], and Jumonji AT-rich
interactive domain 1C (JARID1C) [54].
Our study has several limitations. Firstly, our sample size
is relatively small. Our study does however represent the
first examination of the relationship between BDNF and
brain anatomy in ASD, and is equivalent in sample size to
some of the smaller studies that have been published to date
on BDNF vall66met and brain structure in typically
developing controls [55, 56]. Secondly we were not able
to obtain ADI-R/ADOS confirmation of clinical ASD
diagnosis in all volunteers in our ASD group. However,
this confirmation was available for the majority of people
with ASD, and all ASD diagnoses were made by a
multidisciplinary team trained in the ADI-R and ADOS.
Thirdly, almost all participants with ASD in our study had a
diagnosis of Asperger syndrome, and all had a FSIQ greater
than 70. Further studies in diagnostically homogeneous
samples of people with other ASD diagnoses and cognitive
profiles will be required to establish the generalisability of
our findings across the autism spectrum. Fourthly, people
with ASD and controls differed significantly in general
cognitive ability. Although this means that our findings
may be driven my differences in FSIQ rather than ASD
diagnosis per se, the strong association between ASD and
learning disability complicates the issue of matching for IQ
in study design [57]. Furthermore, in our sample, FSIQ did
not correlate with any of the regional cortical measures
showing group-by-genotype interactions. Fifthly, because
our sample covered a wide age-range, we co-varied for age
in all analyses and were not therefore able to directly model
possible “Group-by-Genotype-by-Age” effects on cortical
anatomy. The age range of our sample and the predomi-
nance of individuals with Asperger syndrome diagnoses
may also account for the fact that we did not observe the
increased cortical volumes commonly reported in autism
[58, 59]. Finally, as our sample included both males and
females we were not able to determine the influence of
gender on our findings.
In summary, our results provide preliminary evidence
that in medial and lateral frontal cortices the relationship
between BDNF val66met genotype and cortical volume is
not the same in people with ASD as it is in typically
developing populations. This may be due to differences
between people with ASD and typically developing
populations in either (i) BDNF val66met genotype frequen-
cies, or (ii) the mechanisms linking this genetic polymor-
phism to regional variations in cortical surface area.
References
1. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of
the autism spectrum in a population cohort of children in South
Thames: the Special Needs and Autism Project (SNAP). Lancet.
2006:368(9531):210–5.
2. Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for
children with autism. Journal of Child Psychology & Psychiatry &
Allied Disciplines. 2004;45(2):212–29.
3. World Health O. Mental disorders; a glossary and guide to their
classification in accordance with the 10th revision of the
international classification of
4. Zwaigenbaum L, Bryson S, Rogers T, Roberts W, Brian J,
Szatmari P. Behavioral manifestations of autism in the first year of
life. Int J Dev Neurosci. 2005;23:143–52.
5. Volkmar FR, Lord C, Bailey A, Schultz RT, Klin A. Autism and
pervasive developmental disorders. J Child Psychol Psychiatry &
Allied Disciplines. 2004;45:135–70.
6. Bailey A, Le Couteur A, Gottesman I, Bolton P. Autism as a
strongly genetic disorder: Evidence from a British twin study.
Psychol Med. 1995;25:63–77.
7. Bauman ML, Kemper TL. Neuroanatomic observations of the
brain in autism: A review and future directions. Int J Dev
Neurosci. 2005;23:183–87.
8. Redcay E, Courchesne E. When is the brain enlarged in autism? A
meta-analysis of all brain size reports. Biol Psychiatry. 2005;58:1–9.
9. Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of
autism. Trends Neurosci. 2008;31:137–45.
10. Wassink TH, Hazlett HC, Epping EA, et al. Cerebral cortical gray
matter overgrowth and functional variation of the serotonin
transporter gene in autism. Arch Gen Psychiatry. 2007;64:709–17.
11. Davis LK, Hazlett HC, Librant AL, et al. Cortical enlargement in
autism is associated with a functional VNTR in the monoamine
oxidase A gene. Am.J.Med.Genet.B Neuropsychiatr.Genet. 2008.
J Neurodevelop Disord (2009) 1:215–223 22112. Binder DK, Scharfman HE. Brain-derived neurotrophic factor.
Growth Factors. 2004;22:123–31.
13. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met
polymorphism affects activity-dependent secretion of BDNF and
human memory and hippocampal function.[see comment]. Cell.
2003;112(2):257–69.
14. Chen WG, Chang Q, Lin Y, et al. Derepression of BDNF
transcription involves calcium-dependent phosphorylation of
MeCP2.[see comment]. Science. 2003;302(5646):885–9.
15. Cheeran B, Talelli P, Mori F, et al. A common polymorphism in
the brain-derived neurotrophic factor gene (BDNF) modulates
human cortical plasticity and the response to rTMS. J Physiol.
2008;586:5717–25.
16. Pezawas L, Verchinski BA, Mattay VS, et al. The brain-derived
neurotrophic factor val66met polymorphism and variation in
human cortical morphology. J Neurosci. 2004;24(45):10099–102.
17. Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink
TH. Cognitive and magnetic resonance imaging brain morpho-
metric correlates of brain-derived neurotrophic factor Val66Met
gene polymorphism in patients with schizophrenia and healthy
volunteers. Arch Gen Psychiatry. 2006;63:731–40.
18. Agartz I, Sedvall GC, Terenius L, et al. BDNF gene variants and
brain morphology in schizophrenia. Am J Med Genet.Part B,
Neuropsychiatric Genetics: the Official Publication of the Inter-
national Society of Psychiatric Genetics. 2006;141(5):513–23.
19. Nemoto K, Ohnishi T, Mori T, et al. The Val66Met
polymorphism of the brain-derived neurotrophic factor gene
affects age-related brain morphology. Neuroscience Letters.397
(1–2):25–9. 2006:17.
20. Varnas K, Lawyer G, Jonsson EG, et al. Brain-derived neuro-
trophic factor polymorphisms and frontal cortex morphology in
schizophrenia. Psychiatr Genet. 2008;18:177–83.
21. Schofield PR, Williams LM, Paul RH, et al. Disturbances in
selective information processing associated with the BDNF
Val66Met polymorphism: Evidence from cognition, the P300
and fronto-hippocampal systems. Biol Psychol. Sep 16 2008.
22. McAlonan GM, Cheung V, Cheung C, et al. Mapping the brain in
autism. A voxel-based MRI study of volumetric differences and
intercorrelations in autism. Brain. 2005;128(Pt 2):268–76.
23. Hadjikhani N, Joseph R, Snyder J, Tager-Flusberg H. Anatomical
Differences in the Mirror Neuron System and Social Cognition
Network in Autism. Cerebral Cortex. 2005:1–7.
24. Nelson KB, Grether JK, Croen LA, et al. Neuropeptides and
neurotrophins in neonatal blood of children with autism or mental
retardation. Ann Neurol. 2001;49(5):597–606.
25. Connolly AM, Chez M, Streif EM, et al. Brain-derived neuro-
trophic factor and autoantibodies to neural antigens in sera of
children with autistic spectrum disorders, Landau-Kleffner syn-
drome, and epilepsy. Biol Psychiatry. 2006;59(4):354–63.
26. Miyazaki K, Narita N, Sakuta R, et al. Serum neurotrophin
concentrations in autism and mental retardation: a pilot study.
Brain Dev. 2004;26(5):292–5.
27. Nishimura K, Nakamura K, Anitha A, et al. Genetic analyses of
the brain-derived neurotrophic factor (BDNF) gene in autism.
Biochem Biophys Res Commun. 2007;356(1):200–6.
28. Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic activity in
autism: abnormalities in the cerebral cortex and basal forebrain.
Am J Psychiatry. 2001;158(7):1058–66.
29. Croen LA, Goines P, Braunschweig D, et al. Brief Report: Brain-
Derived Neurotrophic Factor and Autism: Maternal and Infant
Peripheral Blood Levels in the Early Markers for Autism (EMA)
Study. Autism Res. 2008;1:130–37.
30. Nishimura K, Nakamura K, Anitha A, et al. Genetic analyses of
the brain-derived neurotrophic factor (BDNF) gene in autism.
Biochem Biophys Res Commun. 2007;356:200–6.
31. Rubenstein JL, Rakic P. Genetic control of cortical development.
Cereb Cortex. 1999;9:521–3.
32. Chenn A, Walsh CA. Regulation of cerebral cortical size by
control of cell cycle exit in neural precursors. Science.
2002;297:365–9.
33. Huttenlocher PR. Morphometric study of human cerebral cortex
development. Neuropsychologia. 1990;28(6):517–27.
34. Sowell ER, Thompson PM, Leonard CM, Welcome SE, Kan E,
Toga AW. Longitudinal mapping of cortical thickness and brain
growth in normal children. J Neurosci. 2004;24(38):8223–31.
35. Desikan RS, Segonne F, Fischl B, et al. An automated labeling
system for subdividing the human cerebral cortex on MRI scans
into gyral based regions of interest. Neuroimage. 2006;31(3):968–
80.
36. Han X, Jovicich J, Salat D, et al. Reliability of MRI-derived
measurements of human cerebral cortical thickness: the effects of
field strength, scanner upgrade and manufacturer. Neuroimage.
2006;32(1):180–94.
37. Fischl B, Dale AM. Measuring the thickness of the human
cerebral cortex from magnetic resonance images. Proc Natl Acad
Sci USA. 2000;97:11050–5.
38. Fischl B, Van Der KA, Destrieux C, et al. Automatically
Parcellating the Human Cerebral Cortex. Cereb Cortex. 2004;14
(1):11–22.
39. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I.
Segmentation and surface reconstruction. Neuroimage. 1999;9
(2):179–94.
40. Shaw P, Kabani NJ, Lerch JP, et al. Neurodevelopmental
trajectories of the human cerebral cortex. J Neurosci.
2008;28:3586–94.
41. Toro R, Perron M, Pike B, et al. Brain Size and Folding of the
Human Cerebral Cortex. Cerebral Cortex. 2008:bhm261.
42. Luders E, Narr KL, Thompson PM, et al. Gender differences in
cortical complexity. Nat Neurosci. 2004;7(8):799–800.
43. Lang UE, Hellweg R, Seifert F, Schubert F, Gallinat J. Correlation
Between Serum Brain-Derived Neurotrophic Factor Level and An
In Vivo Marker of Cortical Integrity. Biol Psychiatry.
2007;62:530–5.
44. Nordahl CW, Dierker D, Mostafavi I, et al. Cortical Folding
Abnormalities in Autism Revealed by Surface-Based Morphom-
etry. J Neurosci. 2007;27:11725–35.
45. Murphy DGM, Critchley HD, Schmitz N, et al. Asperger
syndrome: A proton magnetic resonance spectroscopy study of
brain. [References]. Arch Gen Psychiatry. 2002;59:885–92.
46. Levitt JG, Blanton RE, Smalley S, et al. Cortical Sulcal Maps in
Autism. Cereb Cortex. 2003;13:728–35.
47. Hardan AY, Jou RJ, Keshavan MS, Varma R, Minshew NJ.
Increased frontal cortical folding in autism: A preliminary MRI
study. Neuroimaging. 2004;131:263–8.
48. Zhou P, Porcionatto M, Pilapil M, et al. Polarized signaling
endosomes coordinate BDNF-induced chemotaxis of cerebellar
precursors. Neuron. 2007;55:53–68. Jul 5.
49. Kuipers SD, Bramham CR. Brain-derived neurotrophic factor
mechanisms and function in adult synaptic plasticity: new insights
and implications for therapy. Curr Opin Drug Discov Devel.
2006;9:580–6.
50. Lam KSL, Aman MG, Arnold LE. Neurochemical correlates of
autistic disorder: A review of the literature. Res Dev Disabil.
2006;27:254–89.
51. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic
duo in age-related neuronal plasticity and neurodegenerative
disorders. Trends Neurosci. 2004;27:589–94.
52. Sadakata T, Washida M, Iwayama Y, et al. Autistic-like
phenotypes in Cadps2-knockout mice and aberrant CADPS2
splicing in autistic patients. J.Clin Invest. 2007;117:931–43.
222 J Neurodevelop Disord (2009) 1:215–22353. Sadakata T, Kakegawa W, Mizoguchi A, et al. Impaired cerebellar
development and function in mice lacking CAPS2, a protein
involved in neurotrophin release. J Neurosci. 2007;27:2472–82.
54. Adegbola A, Gao H, Sommer S, Browning M. A novel mutation
in JARID1C/SMCX in a patient with autism spectrum disorder
(ASD). Am J Med Genet. 2008;146A:505–11.
55. Frodl T, Schule C, Schmitt G, et al. Association of the brain-
derived neurotrophic factor Val66Met polymorphism with reduced
hippocampal volumes in major depression. Arch Gen Psychiatry.
2007;64:410–6.
56. Sublette ME, Baca-Garcia E, Parsey RV, et al. Effect of BDNF
val66met polymorphism on age-related amygdala volume changes
in healthy subjects. Progress in Neuro-Psychopharmacology and
Biological Psychiatry. 2008.
57. Szatmari P, Zwaigenbaum L, Bryson S. Conducting Genetic
Epidemiology Studies of Autism Spectrum Disorders:
Issues in Matching. J Autism Dev Disorders. 2004;34:49–
57.
58. Hazlett HC, Poe MD, Gerig G, Smith RG, Piven J. Cortical gray
and white brain tissue volume in adolescents and adults with
autism. Biol Psychiatry. 2006;59(1):1–6.
59. Carper RA, Moses P, Tigue ZD, Courchesne E. Cerebral lobes in
autism: early hyperplasia and abnormal age effects. Neuroimage.
2002;16:1038–51.
J Neurodevelop Disord (2009) 1:215–223 223